Donald Peter Wood

Cholestech Corp. provides diagnostic tools and information for risk assessment and therapeutic monitoring of heart disease, inflammatory disorders, and diabetes. It manufactures LDX System, multi-analytic testing system, and accessories to perform individual tests. The company was founded in 1988 and is headquartered in Hayward, CA.

Quidel Corp. engages in the development, manufacture and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions. The firm products are directly sold to end users and distributors and for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies and wellness screening centers. The company was founded in 1979 and is headquartered in San Diego, CA.

ABAXIS, Inc. engages in the development, manufacture, and marketing of portable blood analysis systems. It operates through the following segments: Medical Market, Veterinary Market, and Other. The Medical Market segment serves a customer group consisting of physicians’ office practices across multiple specialties, urgent care, outpatient and walk-in clinics, health screening operations, home care providers, nursing homes, ambulance companies, oncology treatment clinics, dialysis centers, pharmacies, hospital laboratories, military installations, pharmaceutical clinical trials, and cruise ship lines. The Veterinary Market segment focuses on animal hospitals, animal clinics with mixed practices of small animals, birds and reptiles, equine and bovine practitioners, veterinary emergency clinics, veterinary referral hospitals, universities, government, pharmaceutical companies, biotechnology companies, and private research laboratories. The company was founded by Vladimir E. Ostoich in April 1989 and is headquartered in Union City, CA.

Metra Biosystems Inc was a leader in developing and commercializing diagnostic products for the detection and management of metabolic bone diseases and disorders. The company's strategy is to offer a portfolio of tests that will provide physicians with comprehensive clinical information regarding the metabolism of bone and other connective tissues